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ABSTRACT: Background: Immunization is the most cost-effective intervention 
for infectious diseases which are the major cause of morbidity and mortality 
worldwide. There is a scarcity of information on the vaccination status of young 
adults and the role of socioeconomic conditions in India. Objectives: Present study 
explored the adult vaccination status and influence of income and education of 
parents on adult vaccination status in university students from Mumbai, India. 
Methods: On the basis of the eligibility criterion 149 students were selected for the 
present study. A total of 8 vaccines namely Tdap/DTP, Varicella, MMR, Influenza, 
Pneumococcal, Hepatitis A, Hepatitis B and Meningococcal were included in this 
study for all the respondents. In addition to these vaccines, Human Papilloma Virus 
vaccine was also included for female respondents. Results: There were total of 149 
(75 male and 74 females) respondents with the mean age of 21.5 years. The top 3 
immunizations were Td/Tdap (97.3%), MMR (66.4%) and Hepatitis B (55%) among 
the respondents. Only 4 (5.5%) female respondents have been immunized against the 
HPV. Conclusions: Td/Tdap (97.3%) and MMR (66.4%) coverage was in line with 
the recommendations. For all the other vaccines the coverage was low varying from 
5.5% to 35.4%. The vaccination coverage was better in respondents with higher 
educated and higher income parents. We suggest that patient education, planning by 
government for the implementation of policy for adult vaccination and involvement 
of physicians are must for better adult vaccination coverage. 
INTRODUCTION:  “When meditating over a 
disease, I never think of finding a remedy for it, but 
instead a means of preventing it” Louis Pasteur. 
Immunization is the most cost-effective 
intervention for infectious diseases which are the 
major cause of morbidity and mortality worldwide. 
Vaccines not only protect the individual who is 
vaccinated but also reduce the burden of infectious 
vaccine preventable diseases for the entire 
community.
1
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Vaccination of adults is very important given that 
>25% of mortality is due to infectious diseases. 
Vaccines are recommended for adults on the basis 
of age, prior vaccinations, health conditions, 
lifestyle, occupation, and travel. 
2
 There have been 
significant efforts to curb morbidity, mortality, and 
disability among adults particularly due to 
communicable diseases such as tetanus, diphtheria, 
pertussis, hepatitis A, hepatitis B, human papilloma 
virus, Japanese encephalitis, measles, mumps, 
rubella, meningococcus, pneumococcus, typhoid, 
influenza, and chickenpox. Nevertheless, in a 
developing country like India, communicable 
diseases contribute to a large burden morbidity, 
mortality, and disability. 
3
  
Immunization for infants worldwide has led to 
important long term effects on the traditional 
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epidemiological patterns of major infectious 
diseases. Countries have found that vaccine 
induced immunity may not have the same long 
term stability as disease induced immunity, raising 
the average age of incidence for various vaccine 
preventable diseases.
4
 Many childhood vaccine 
preventable infections are now found among adults. 
A massive diphtheria epidemic occurred in the 
former Soviet Union with more than 1,57,000 cases 
and 5000 deaths. A majority of cases throughout 
this epidemic occurred in persons > 15 yrs old and 
adults from 40 to 49 yrs old had very high 
incidence and death rates. 
4
 Both in resource rich 
and resource poor countries, outbreaks of measles, 
mumps and rubella have caused major disruptions 
on college campuses, in the workplace and in 
institutions.
4
  
The government of India as well as the WHO 
considers childhood vaccination as the leading 
priority. However, there is no focus on adult 
immunization, 
5-7
 which also is the most ignored 
part of healthcare services in India. A recently 
published ‘National Vaccine Policy – 2011’ by the 
India Ministry of Health and Family Welfare, 
Government
8
 gives guidelines to policy makers and 
program managers regarding various strategies for 
strengthening the ‘Universal Immunization 
Programme’, but the main focus is on children not 
adults.  
Vaccine-preventable diseases cause unnecessary 
morbidity and mortality among adults in the 
region.
9
 Adult vaccination coverage in India is 
negligible; even in a developed country like US, 
the coverage is only 2% of the adult population. 
The economically productive adult populations 
have been denied the full benefit of personal 
protection owing to either non-availability of 
vaccines or those receiving vaccines not being 
protected to the fullest extent due to incomplete 
effectiveness of available vaccines. Protecting 
adults by vaccination has never been considered in 
India a preventive strategy likely to have a great 
impact on population health.
10
 While inadequate 
immunization results in unnecessary costs, 
including those associated with hospitalization, 
treatment, and loss of income 
9
, studies have also 
shown that education status and socioeconomic 
profile is an important determinant associated with 
adult immunization.
11, 4, 12
  
Rationale: There is a scarcity of information on the 
vaccination status of young adults and the role of 
socioeconomic conditions in India. We through our 
University research collaborations in Mumbai, 
India wish to explore the vaccination status of 
university students and probable role of 
socioeconomic factors in Mumbai, India.  
METHOD: 
Study design and respondents: This descriptive 
study was performed in January – April 2015, 
among under graduate pharmacy students from 
Mumbai University, India way of a questionnaire. 
The study protocol was approved by V. V. research 
Independent Ethics Committee, Mumbai, India. 
Students were contacted by study team member in 
their classrooms and were given a brief 
introduction about the research project. Those who 
desired to participate were explained the purpose 
and objectives of the study. On the basis of the 
eligibility criterion (those who gave a written 
informed consent and are between the age group of 
18-25 years) 149 students were selected for the 
present study.  
Study instrument: The survey questionnaire was 
prepared in English after reviewing the literature 
for similar studies. The questionnaire was framed 
to gather information on age, gender, and vaccines 
taken by each participant after 18 years of age. 
Information on the monthly family income, and 
educational qualification of parents was also 
requested for each participant in the questionnaire. 
A total of 8 vaccines namely Tdap/DTP, Varicella, 
MMR, Influenza, Pneumococcal, Hepatitis A, 
Hepatitis B and Meningococcal were included in 
this survey for all the respondents. In addition to 
these vaccines, Human Papilloma Virus vaccine 
was included for female respondents. 
The validity of the survey questionnaire was 
evaluated in the pilot study with a sample of 30 
students. This was done to get the average time 
required for face to face interview for completing 
the questionnaire and to ensure that it is appropriate 
and understandable to students. Pilot population 
was not part of the final study.  
Collection of data: Students were visited at their 
house with prior appointment by a study team of 5 
trained master of pharmacy students. The purpose 
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of the research was explained to the respondents, 
anonymity and confidentiality were guaranteed and 
maintained. The researchers complied with the 
international ethical guidelines for research. The 
data was recorded into the predesigned case report 
form by interviewers. The vaccination status data 
was cross verified against the vaccination records 
of each participant.  
Data entry and analysis: Collected data from 
individual CRF was entered into Microsoft excel 
and was verified by the authors other than 
interviewers. The data were analyzed by Microsoft 
excel for finding out relevant statistics (Mean, 
standard deviation, frequencies and percentage). 
Qualitative variables were presented as frequencies 
and percentages to observe their relationship with 
vaccination status. 
RESULTS: Table 1 shows the socio-demographic 
parameters of study respondents from Mumbai. 
There were total of 149 (75 male and 74 females) 
respondents with the mean age of 21.5 years. 78 
(52.7%) respondents belonged to the monthly 
family income group of 50,000 to 100,000 INR.  
TABLE 1: SOCIO-DEMOGRAPHIC CHARACTERISTICS 
OF RESPONDENTS 
n= 149, Cohort mean age = 21.5 years 
Male = 75; mean age = 22 years 
Females = 74; mean age = 21 years 
Family income (148 respondents) 
Monthly family income 
In Indian Rupee (INR) 
Frequency (%) 
< 50,000 33 (22.3) 
50,000 to 100,000 78 (52.7) 
> 100,000 37 (25) 
Parent’s education (139 respondents) 
Education score of parents Frequency (%) 
0 0 0 
0.5 2 1.3 
1 9 6.5 
1.5 7 5.1 
2 11 7.9 
2.5 8 5.7 
3 10 7.2 
3.5 4 2.9 
4 54 38.9 
4.5 21 15.1 
5 13 9.4 
For calculating education score following formula 
was used. Parent’s education score = (Father’s 
education score + Mother’s education score) / 2.  
Scoring was as follows: education less that 
secondary school = 0, secondary school = 1, high 
school = 2, Diploma = 3, Bachelor’s degree = 4, 
Master’s degree and above = 5. In case data was 
available for only one parent, other parent’s 
education score was considered zero. Maximum 
respondents 54 (38.9%) had parental education 
score of 4, followed by 21 (15.1%) respondents 
with parental education score of 4.5. 
As seen from Table 2, the top 3 immunizations 
were Td/Tdap (97.3%), MMR (66.4%) and 
Hepatitis B (55%) among the respondents. Only 4 
(5.5%) female respondents have been immunized 
against the HPV. 
TABLE 2: VACCINATION STATUS OF 
RESPONDENTS 
Vaccine 
(n = number of respondents) 
Frequency 
(%)vaccinated 
Td/T dap n=149 145 (97.3) 
Varicella n=149 45 (30.2) 
MMR n=149 99 (66.4) 
Influenza n=147 52 (35.4) 
Pneumococcal n=148 22 (14.9) 
Hepatitis A n=149 76 (51) 
Hepatitis B n=149 82 (55) 
Meningococcal n=148 15 (10.1) 
Human Papilloma Virus only for females n=73 4 (5.5) 
Table 3 presents vaccination status categorized by 
monthly family income (INR). As seen in Fig. 1, 
income group (< 50,000 INR/month) had lowest 
vaccination percentages for all the vaccines, except 
for MMR and HPV. In case of MMR, vaccination 
percentages for all three income groups were 
almost similar. Only 1 (6.2%) respondent from 
income group of < 50,000 INR/month and 3 (8.1%) 
respondents from income group of > 100,000 
INR/month had vaccinated against HPV. 
FIG. 1: MONTHLY FAMILY INCOME (INR) AND 
VACCINATION STATUS OF RESPONDENTS  
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TABLE 3: MONTHLY FAMILY INCOME (INR) AND VACCINATION STATUS OF RESPONDENTS   
 < 50,000 INR 
n = 33 
50,000 to 100,000 INR 
n = 78 
> 100,000 INR 
n = 37 
 Frequency % Frequency % Frequency % 
Td/T dap 31 93.9 77 98.7 36 97.3 
Varicella 8 24.2 28 35.9 7 18.9 
MMR 22 66.7 51 65.4 25 67.6 
Influenza 10 31.3 25 32.5 16 43.2 
Pneumococcal 3 9.1 14 18.2 4 10.8 
Hepatitis A 12 36.4 39 50 24 64.9 
Hepatitis B 14 42.4 42 53.8 25 67.6 
Meningococcal 2 6.1 8 10.4 4 10.8 
Human Papilloma Virus vaccine 
(only for females) 
1 
n= 16 
6.2 
 
0 
n= 38 
0 
 
3 
n= 19 
8.1 
 
 
Table 4 shows parent’s education and vaccination 
status of the respondents. Vaccination % is lesser 
for respondents with parent’s education of < high 
school than those with parent’s education score of 
graduate and above, except for Pneumococcal 
vaccine (Fig. 2). HPV vaccination has been taken 
only by respondents 4(8.5%) with parent’s 
education of graduate and above. 
 
TABLE 4: PARENTAL EDUCATION SCORE AND VACCINATION STATUS OF RESPONDENTS.  (n=139) 
Education 
Score of 
parents 
Number of 
respondents 
Frequency 
(%) 
Td/Tdap Varicella 
 
MMR Influenza Pneumococcal HAV HBV Meningococcal HPV 
< High 
School 
18(12.9) 15(83.3) 3(16.7) 8(44.4) 6(33.3) 4(22.2) 6(33.3) 6(33.3) 1(5.6) 0 
n=10 
High School 
to < 
Graduation 
33(23.7) 33(100) 5(15.2) 24(72.7) 10(30.3) 5(15.2) 17(51.5) 19(57.6) 3(9.1) 0 
n=17 
Graduate 
and above 
88(63.3) 88(100) 31(35.2) 60(68.1) 31(35.2) 14(15.9) 51(57.9) 51(57.9) 9(10.2) 4(8.5) 
n=47 
Abbreviations: Td/Tdap (Tetanus, Diphtheria and Pertussis vaccine), MMR (Measles, Mumps and Rubella vaccine), HAV 
(Hepatitis A Virus vaccine), HBV (Hepatitis B Virus vaccine), HPV (Human Papilloma Virus vaccine).   
 
 
FIG. 2: PARENT’S EDUCATION AND VACCINATION 
STATUS OF RESPONDENTS 
 
DISCUSSION: Although it is well known that 
disease prevention is the most cost-effective option 
to protect and promote health of populations and 
immunization is the key to achieve the same, adult 
vaccination has never been considered a preventive 
strategy likely to have a great impact on population  
 
health. Authors discuss below our findings in the 
light of recommendations by the expert group of 
API.  
 
Vaccines’ recommended by Expert group. 
Td/Tdap 
Diphtheria: In the 1990s, a large epidemic of 
diphtheria began in Russia and subsequently spread 
to the Newly Independent States (NIS) of the 
former Soviet Union. About two-thirds of the 
reported cases occurred among persons ≥15 years 
of age. In Ukraine too, at the peak of the epidemic 
in 1995, more than 80% cases were reported in the 
same age group 
13-16
. In fact, serologic studies in 
the 1980s from these countries had suggested that 
>50% of adults were susceptible to diphtheria.
17, 18
 
Since then, diphtheria immunity among adults 
became an important issue.  
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Tetanus: Tetanus too remains an important public 
health problem in many parts of the world, 
particularly in the tropical developing countries. In 
2008, the total number of deaths caused by tetanus 
worldwide was estimated to be more than 61,000. 
19
 In India, DTP vaccine was introduced in routine 
immunization in 1978, resulting in substantial 
decline in incidence in the pediatric populations. 
The effect was a shift of the infection to the older 
age groups. The age shift justified the need of 
booster diphtheria immunization. 
20
  
Pertussis: Pertussis is generally considered as a 
childhood disease but was well documented in 
adults during the twentieth century. 
21-23
 In the 
United States, there have been reports of pertussis 
among adolescents and adults. 
24, 25
 In India, there 
are no reports of pertussis in adults yet but chances 
are that these cases are not detected and the 
susceptibility is also not known.  
There have been increasing reports of pertussis out 
breaks in adult’s population in many western 
countries and vaccination of this group is being 
planned. 
26
 Like many other developing countries 
of the world, morbidity and mortality rate due to 
pertussis is likely to be high in South Asian 
countries such as Pakistan, India, Bangladesh and 
Sri Lanka as well as countries of African continent. 
27-29
 There is also a very high probability of 
occurrence of adult’s pertussis case in this region. 
Furthermore there is an overall lack of data related 
to laboratory confirmed cases of pertussis from 
these regions. The main reason behind this under 
reporting may be due to lack of adequate diagnostic 
facilities, poor surveillance systems and 
unawareness of physicians to the occurrence of 
these infections in adult population. Widespread 
use of DPT vaccination has resulted in the shifting 
of incidence of pertussis to adolescents and adults. 
30
 It is estimated that almost 20- 50% of all 
persistent cough cases in adults are caused by the 
B. pertussis. 
31, 32 
Adult pertussis is both a 
significant health problem as well as an economic 
burden in both developing as well as developed 
countries. 
33
 
In spite of good immunization coverage, the 
developed countries have shown a shift in the 
epidemiology of the disease to the adolescent and 
the adult age group, leading to a revision of their 
vaccination policies. 
34
 The anticipation and early 
recognition of this change in the epidemiology is 
important because the affected adolescents and 
adults act as reservoirs of the disease to the 
vulnerable population of infants, for whom the 
disease can be life threatening. 
35
 Research in 
several countries had shown that pertussis is 
endemic among the adolescents and adults. It is 
suggested that a universal program of adolescent 
and adult boosters would decrease the circulation 
of B. pertussis in these age groups and possibly 
could lead to the elimination of the organism from 
the population. 
36
  
API 
37
 has recommended routine Tdap vaccination 
for all adults not immunized earlier. For all adults 
in the age group of 18 to 64 years who have 
completed their childhood vaccination schedule, a 
booster dose of Td vaccine is indicated once every 
10 years till the age of 65 years; one dose of Tdap 
vaccine may be administered in place of Td 
vaccine. For adults aged over 18 years who have 
not received prior vaccination against diphtheria, 
pertussis and tetanus, three doses of Td vaccine are 
indicated. 
Our results are encouraging in the light of API 
recommendation, wherein 145 (97.3%) of the 
respondents were immunized against DTP.  
Varicella: Although VZV is an extremely common 
infection worldwide, its epidemiology is markedly 
different in tropical and temperate climates. While 
in temperate countries, the vast majority of the 
population have seroconverted by adolescence 
38, 39
 
in tropical countries, seroconversion generally 
occurs in late adolescence and adulthood. 
40
 Several 
seroprevalence studies in Southeast Asia have 
indicated that a significant proportion of the 
population remain susceptible to VZV infection 
well into adulthood. In Singapore, serological 
surveys have revealed that only 41% of those aged 
15-24 years have protective antibodies to VZV, 
while >90% seroprevalence is not reached until the 
age of 35 years and over. 
41
 Similar results have 
been obtained in Malaysia 
42
, the Philippines 
43
 and 
Thailand. 
44
 Incidence data reflect low 
seroprevalence among adolescents and adults in the 
region. 
41, 45
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Reports from South India 
46, 47
 have revealed that 
close to 30% of adolescents above 15 years are 
susceptible to VZV infection. Multicentric study 
from India showed that Varicella susceptibility 
extended even into the 30-40 years of age group.
48
  
The susceptibility to VZV of many adults in 
Southeast Asia due to late seroconversion, together 
with the heightened risk of complications, 
hospitalization and death, provide strong support 
for the vaccination of seronegative adults. Ideally, 
all adults and adolescents who did not have 
chickenpox as children should receive the vaccine.
9
  
Persons aged over 13 years without evidence of 
varicella immunity should receive 2 doses of the 
vaccine 4-8 weeks apart. Those who have received 
one dose of vaccine in childhood are advised to get 
their second dose. 
37
 
Introduction of varicella vaccination in USA has 
resulted in a clinically and statistically significant 
reduction in varicella-related hospitalizations for 
adults and a corresponding significant decrease in 
hospital charges. 
49
  
Our results have shown that minimal 45(30.2%) 
respondents were immunized against varicella.  
There needs to be implement the API 
recommendations to prevent the varicella 
associated complications, hospitalizations and 
deaths.  
MMR: Measles is an infectious disease caused by 
Morbillivirus, with a secondary attack rate in 
excess of 80%, that usually affects children.
50
 
However, multiple outbreaks of the disease have 
even been reported among adults in heterogeneous 
settings (urban areas, university campuses, disaster 
sites, during international travel, etc.). 
51-54
 Mumps, 
though historically a disease of childhood, present 
outbreaks of mumps predominantly involves young 
adults, nearly all of whom had been vaccinated, 
most with the two dose schedule.
55
 
Rubella is an acute, usually mild, viral disease 
traditionally affecting susceptible children and 
young adults worldwide. Targeting rubella for 
elimination.
55
  
Our study revealed that moderate number of 
respondents 99 (66.4%) received one dose of MMR 
vaccine.  It is necessary to follow the expert group 
recommendations that all adults (except those who 
have medically documented history of having 
suffered from all the three disease; those who have 
received two doses of MMR vaccine in the 
childhood; and those with any contraindications for 
receiving this vaccine), should receive one dose of 
the MMR vaccine. 
37
  
Optional Vaccines by expert group: 
Influenza: Our results showed that minimal 
number of respondents 52(35.4%) were immunized 
against influenza. Although, the burden of 
influenza-associated morbidity and mortality is 
now recognized in many developed countries, data 
on influenza in most developing countries remain 
sparse. A study conducted by Hirve 
56
 in northern 
(Ballabgarh) and western (Vadu) India to estimate 
and compare incidence of influenza-associated 
hospitalization showed that influenza-associated 
hospitalization rates were highest among infants 
and adults aged >60 years in Ballabgarh, whereas 
rates were higher among older children and young 
adults in Vadu. Peak detection of influenza viruses 
among hospitalized patients coincided with periods 
of peak rainfall in both communities. The markedly 
different influenza hospitalization rates by season 
and across communities in India highlight the need 
for sustained multi-site surveillance system for 
estimating national influenza disease burden. That 
would be the first step for initiating discussions 
around Influenza prevention and control strategies 
in the country.
56
 In the absence of epidemiological 
surveillance regarding the influenza serotypes in 
India, the use of influenza vaccine in India is not 
recommended by API.
37
 
Pneumoccocal: The scientific evidence for the 
efficacy of PPV has been a very controversial 
issue. This is attested by the fact that more than 15 
meta-analyses with conflicting results have been 
published so far on the efficacy of PPV in adults. 
37
 
The Expert Group observed that the available 
evidence is insufficient to recommend routine use 
of PPV in adults. Although PPV is efficacious in 
preventing invasive pneumococcal disease among 
adults, routine PPV administration to adults is not 
likely to be cost-effective in India. Given the lack 
of credible scientific evidence supporting the 
efficacy of PPV in high-risk populations and a 
complete lack of published data on the population 
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at risk of invasive pneumococcal disease and 
community acquired pneumonia among the adults 
in India, the Expert Group has endorsed the recent 
recommendations by the WHO against the use of 
PPV among adults. 
37 
This is in tune with our 
results showing that minimal number of 
respondents 22(14.9%) have taken Pneumococcal 
vaccine. 
Hepatitis:  
Hepatitis A: With improvement in economic and 
living conditions of the communities, the age of 
acquiring hepatitis A virus (HAV) infection is 
shifting from early childhood to adolescence and 
young adulthood. Data from India indicate that the 
population is no longer homogeneous for its HAV 
exposure profile. Occasional outbreaks of HAV 
and higher proportions of symptomatic cases are 
reported amongst older children and adults from 
different regions of the country. However, the 
heterogeneous exposure to HAV defies widespread 
use of the vaccine. The challenge is to recognize 
the susceptible pockets and take pre-emptive steps. 
In regions with rapid improvement in living 
standards and environmental hygiene, there is a 
need for regular surveillance through structured 
protocols that are able to identify early signs of 
epidemiological shift. 
57
  
The Expert Group conveys that universal 
immunization for hepatitis A is not recommended 
as yet. Not only is the vaccine costly, more 
epidemiological data are required to ascertain its 
benefits. 
37
 In the present study 76(51%) of the 
respondents have taken Hepatitis A vaccine.  
Hepatitis B: 82(55%) of the respondents were 
immunized against Hepatitis B. API recommends 
that Hepatitis B vaccination is indicated for all 
unvaccinated adults at risk for HBV infection and 
all adults seeking protection from HBV infection 
including post-exposure prophylaxis. 
37
 
Unvaccinated adults who are at risk for HBV 
infection include, for example patients with 
percutaneous or mucosal exposure to blood; 
patients with sexual exposure, persons at risk for 
occupational exposure to HBV patients who are 
HIV-seropositive, patients with CLD, chronic 
kidney disease (CKD) etc. 
37
 Hepatitis A and B 
move than 50% vaccination coverage can be in part 
explained by the recent Hepatitis awareness 
campaigns involving celebrities organized in 
various states of India.   
Meningococcal: 15(10.1%) of the respondents had 
taken Meningococci vaccine. This is in tune with 
the recommendation of the expert group of the 
Association of Physicians of India 
37 
that routine 
vaccination of all adults is not recommended in 
view of the short lived protection provided by the 
currently available polysaccharide vaccines. The 
meningococcal vaccine can be used in selected 
populations in certain situations such as during an 
outbreak, during inter epidemic periods to persons 
living in dormitories and immunocompromised 
individuals, to travelers, pilgrims, people attending 
fairs and festivals in large numbers. 
37
  
HPV: Our results have shown that only 4(5.5%) of 
the female respondents have taken HPV vaccine.  
Expert group recommends that HPV vaccine has to 
be delivered prior to exposure to the HPV virus. 
Therefore, the immunization must precede the 
sexual debut. The Expert Group recommends the 
age for initiation for vaccination to be 10 - 12 years 
(Level Ib, Grade A). Catch-up vaccination can be 
advised up to the age of 26 years for Gardasil® 
vaccine and 45 years for Cervarix® vaccine (Level 
Ib, Grade A). The HPV vaccines can be given 
simultaneously with other vaccines e.g., Hepatitis 
B, Tdap (Level IIa, Grade B).
37
 Currently available 
HPV vaccines do not protect against HPV types 
found in approximately 30% of cervical cancers. 
Although HPV vaccination is a promising control 
option, it will take several decades to establish its 
effect on cervical cancer burden and the vaccine 
costs are currently prohibitive. Timely 
implementation of an affordable and effective 
screening strategy in developing countries is thus 
crucial, while waiting for further improvements in 
HPV testing, vaccine technology, costs, and its 
widespread use. 
58
  
CONCLUSION: Our results in terms of 
vaccination coverage have varied from 30.2% 
(varicella) to 97.3% (Tdap) for recommended 
vaccines and 5.5% (HPV) to 55% (Hepatitis B) for 
optional vaccines. In the adult vaccination study 
done by Nacar 
59
 in Turkey vaccination rates were 
lesser compared to present study for Influenza 
(7.8% Turkey & 35.4% India) , Pneumonia (0.4% 
Turkey & 14.9% India), Hepatits B (25.6% Turkey 
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& 25.6% India) and HPV (1.1% Turkey & 5.5% 
India).  
Undergraduate students in India are financially 
dependent on their parents not only for their 
education, but also for health care and all the other 
living costs. Hence we thought it is important to 
look at parent’s education and family income as 
factors which might affect the vaccination status of 
students.  
It is well documented that individuals who are 
more disadvantaged benefit less than those who are 
better off from preventive health interventions. 
60, 61
 
Lower socioeconomic status, as measured by 
education or income, was associated with lower 
immunization rates for influenza. 
62, 63
 In the US, 
vaccination rates were lower among minority 
populations. 
64, 65
 Identifying and matching 
inequalities and barriers is therefore an important 
step in understanding and improving immunization 
rates. Uddin M 
66
 has shown that increasing 
parental educational attainment was significantly 
associated with a trend in higher vaccination uptake 
among students. The effect of parental educational 
status on vaccination rates can carry over to 
offspring, even among those who attain college 
student status.  
Our results have also shown that vaccination 
percentages were lowest for the family income 
group of <50,000 INR/month. Also it was lower for 
respondents with parent’s education of < high 
school than those with parent’s education score of 
graduate and above, except for Pneumococcal 
vaccine (Fig. 2). HPV vaccination has been taken 
only by respondents with parent’s education of 
graduate and above that also by very less number 
of females 4 (8.5%).  This is in tune with the above 
mentioned finding from various studies relating 
vaccination coverage and socioeconomic 
conditions.  
A number of factors are responsible for limited 
growth and penetration of vaccines in India. There 
is lack of epidemiological data on vaccination 
coverage of adults in India. As per author’s 
knowledge this is the first study to assess the 
vaccination coverage in adults in India. This 
variation can be attributable to number of factors 
such as  
1. Unclear process in introducing new vaccines – 
Government of India provides vaccines to 
public through UIP (Universal Immunization 
Program). But the process of inclusion of new 
vaccines in UIP is unclear, slow and is limited 
by funding. 
67
 
 
2. Lack of awareness – Physicians and patients 
have limited knowledge of vaccines. Vaccine 
sales teams do not cover general physicians. 
Other than successful polio vaccination 
program Indian government has not taken up 
any other major vaccination awareness 
campaigns. 
67
 
 
3. Physicians and patients preferences – 
Physicians do not prescribe options vaccines to 
avoid the liability in case of side effects. 
Patients prefer treating rather than preventing 
diseases. 
67
 
 
4. Affordability issues – Vaccines are provided 
free under UIP program but only for highly 
communicable and life threatening diseases. 
Obtaining vaccines through private system is 
expensive and medical insurance policies do 
not cover vaccines. 
67
 
 
5. Lack of data – A lack of quality data on disease 
burdens and vaccine efficacy is the biggest 
obstacle in vaccine coverage in India. Decision 
makers in India, need the safety and 
effectiveness of vaccines in the local 
population. 
67
 
 
6. Limitations in distribution and supply – 
distribution is hampered by inadequate cold 
chains and constrains to last mile distribution. 
Storage in the clinics is limited due to frequent 
electricity blackouts in India. 
67
 
Although immunization against infectious diseases 
is a lifelong process, it is not seen as a health issue 
for adults. Taking into consideration the benefits it 
brings to the individual and the community, and the 
costs that preventable diseases can bring to a 
society, adult vaccination is a very important issue. 
Taking into account the varied vaccination 
coverage rates observed in the present study, it can 
be said that there is a need for nation-wide 
regulations regarding vaccination.  
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Success in adult vaccination can be obtained by 
increasing knowledge in the community in general, 
by developing national policies, and by enabling 
doctors and health personnel to suggest vaccination 
to adults when necessary.  
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